SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PTC Therapeutics -- PTCT
PTCT 68.31+0.3%Oct 31 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (5)1/26/2014 11:58:34 AM
From: scaram(o)uche  Read Replies (1) of 38
 
This brilliant exchange on twitter today re. CD123 (MGNX, XNCR)....

Andy Biotech ?@AndyBiotech 18h
@DrMiguelPerales Penn CD123 CART showed nice efficacy in mice but also clear BM tox, heard they won't pursue further ash.confex.com

Reply
Retweet

Favorite


More


Expand



Miguel Perales M.D. ?@DrMiguelPerales 18h
@AndyBiotech BM Toxicity of CD123 CART could be built into Allo-HCT conditioning - need to make sure CART are gone when donor graft goes in

Reply
Retweet

Favorite


More


Expand



Andy Biotech ?@AndyBiotech 18h
@DrMiguelPerales Thx! Is it better to target CD123 w mAbs, bi-specific CD3xCD123 Abs or ADCs given the safety concerns and narrow Tx window?

Reply
Retweet

Favorite


More


Expand



Miguel Perales M.D. ?@DrMiguelPerales 18h
@AndyBiotech Pros & cons to bi-spec Abs vs CART in general. At this stage, we should explore both. For CD123 bi-spec may have better profile

Reply
Retweet

Favorite


More


Expand



Andy Biotech ?@AndyBiotech 18h
@DrMiguelPerales Agreed and it's clearly on industry's radar, both $MGNX and $XNCR have CD123 bi-spec in development ash.confex.com

Hide conversation Reply
Retweet

Favorite


More




2Retweets
1Favorite
jjz Miguel Perales M.D.

9:43 AM - 26 Jan 2014 · Details
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext